eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials

Daojun Zhang
1
,
Guangqiao He
1
,
Tian Qian
1
,
Fei Hao
1
,
Liwei Liu
2

1.
Department of Skin Plastic Surgery and Beauty, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China
2.
Chongqing Shapingba District People’s Hospital, Chongqing, China
Adv Dermatol Allergol 2022; XXXIX (5): 872-876
Online publish date: 2021/10/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The efficacy of abrocitinib for atopic dermatitis remains controversial.

Aim: We conducted a systematic review and meta-analysis to explore the influence of abrocitinib versus placebo on the treatment of atopic dermatitis.

Material and methods
We searched PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases up to June 2021 for randomized controlled trials (RCTs) assessing the effect of abrocitinib versus placebo for patients with atopic dermatitis. This meta-analysis was performed using a random-effect model.

Results
Four RCTs involving 932 patients were included in the meta-analysis. Overall, compared with the control group for atopic dermatitis, abrocitinib has a remarkably positive impact on IGA response (OR = 6.60; 95% CI: 4.41–9.87; p < 0.00001), EASI-75 (OR = 9.19; 95% CI: 6.20–13.61; p < 0.00001), EASI-90 (OR = 10.50; 95% CI: 5.54–19.93; p < 0.0001), NRS response (OR = 6.99; 95% CI: 4.43–11.01; p < 0.00001) and adverse events (OR = 1.76; 95% CI: 1.23–2.52; p = 0.002), but showed no obvious influence on serious adverse events (OR = 0.53; 95% CI: 0.20–1.44; p = 0.22).

Conclusions
Abrocitinib exerts a favorable effect on the treatment of atopic dermatitis.

keywords:

abrocitinib, atopic dermatitis, randomized controlled trials, meta-analysis

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.